Test Price
2,800 AED✅ Home Collection Available
GRM1 Gene Spinocerebellar Ataxia Type 13, Autosomal Recessive Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Assurance: Diagnostic sensitivity up to 99.9% via ISO-certified laboratory processing.
- Premium Logistics: Hospital-grade home blood collection with ISO-certified cold chain and VIP mobile phlebotomy.
- Clinical Guidance: Post-test telephonic consultation to interpret results with a healthcare specialist.
- Insurance: Direct insurance coverage verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GRM1 Gene NGS Test identifies pathogenic variants causing Spinocerebellar Ataxia Type 13, an autosomal recessive disorder marked by progressive cerebellar degeneration. This definitive molecular analysis enables accurate diagnosis, informed genetic counselling, and tailored management for affected individuals and their families in the UAE.
| Feature | Our Test (GRM1 NGS) | Closest Alternative (Ataxia Multi‑Gene Panel / WES) |
|---|---|---|
| Precision | 100% coverage of all coding exons and splice sites of the GRM1 gene | Broad panel may miss deep intronic or regulatory variants specific to GRM1 |
| Method | Next Generation Sequencing (NGS) with Sanger confirmation | NGS panel or Whole Exome Sequencing – often requires additional targeted confirmation |
| Turnaround Time | 3 – 4 Weeks | 8 – 12 Weeks typical for WES; panel may be faster but less focused |
| Cost | 2,800 AED | 4,500 – 8,000 AED for comparable clinical-grade analysis |
| Interpretation | Focused clinical report with ACMG variant classification | Incidental findings may require separate genetic counselling |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I recognise the profound anxiety that accompanies the suspicion of a hereditary ataxia. This dedicated GRM1 NGS test provides a precise molecular diagnosis, guiding accurate genetic counselling and personalised management. I strongly recommend that you discuss these results with a specialist to develop a compassionate, evidence-based plan.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Medication Advisory
Refrain from discontinuing any prescribed neurological medications without consulting your physician. Sudden withdrawal of anti‑spasticity drugs or other neurological medications may lead to severe rebound symptoms.
⚠️ Exclusion Criteria & Emergency Red Flags
- Recent blood transfusion or bone marrow transplant (within 8 weeks)
- Inability to provide valid informed consent or lack of legal guardian
- Emergency Red Flags: sudden loss of ambulation, acute vision loss, new-onset seizures, severe dysphagia, or respiratory compromise – seek immediate medical attention
Patient FAQ & Clinical Guidance
1. What is the GRM1 gene test for Spinocerebellar Ataxia Type 13?
The GRM1 gene test definitively detects pathogenic variants causing autosomal recessive Spinocerebellar Ataxia Type 13 (SCAR13), a rare inherited movement disorder. This NGS‑based analysis reads the entire coding region of the GRM1 gene to pinpoint disease‑causing mutations. A positive result confirms the diagnosis, guides prognosis, and facilitates family cascade testing.
2. How should I prepare for the GRM1 genetic test?
No fasting or medication adjustment is required; simply provide a blood sample, extracted DNA, or a dried blood spot FTA card. A genetic counselling session is strongly recommended beforehand to draw a detailed pedigree and discuss the implications of autosomal recessive inheritance. Our home collection team will guide you through the process and ensure cold‑chain transport.
3. When will I receive my results and who will interpret them?
Results are delivered within 3 to 4 weeks in a comprehensive clinical report that classifies variants according to ACMG guidelines. The report includes a clear interpretation of whether a disease‑causing mutation was detected. A post‑telephonic consultation with a genetic counsellor or neurologist is included to explain the findings and recommend next steps.
UAE Regulatory & Data Privacy Adherence
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139)
- DHA Licensed Facility: 1143
Clinical & Logistical Metadata
| Test Name | GRM1 Gene Spinocerebellar Ataxia Type 13, Autosomal Recessive Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | G11.2 |
| LOINC Code | 21615-1 |
| DHA Facility License & Laboratory Address | DHA License 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians